What question did this study set out to answer?

To determine if routine measurement of lipoprotein(a) changes management in lipid clinics without specific therapy for Lp(a).

February 14, 2026

Does routine measurement of lipoprotein(a) in a UK lipid clinic alter management in the absence of Lp(a)-specific therapy?

Key Points

To determine if routine measurement of lipoprotein(a) changes management in lipid clinics without specific therapy for Lp(a).
Conducted Lp(a) testing in a UK lipid clinic.
Evaluated alterations in management following test results.
Performed cost-effectiveness modelling for one-time Lp(a) testing.
Routine Lp(a) testing significantly alters management decisions.
Identified residual dyslipidaemia that standard therapies do not address.
Cost-effectiveness modelling indicates savings for the NHS and society.

Abstract

Routine Lp(a) testing meaningfully alters management and reveals a form of residual dyslipidaemia resistant to standard therapy. These findings, combined with recent cost-effectiveness modelling showing NHS and societal savings from one-time testing, support incorporation of Lp(a) measurement into universal cardiovascular risk assessment.

Bookmark

Cite This Study

Tridimas et al. (Wed,) studied this question.

synapsesocial.com/papers/699010ce2ccff479cfe56f5f https://doi.org/https://doi.org/10.1080/03007995.2026.2627735

Bookmark